Bristol-Myers Squibb Co.'s Opdivo in combination with Seattle Genetics Inc.'s Adcetris showed disease reduction in 83% of patients in an ongoing phase 1/2 clinical trial to treat relapsed or refractory Hodgkin lymphoma.
Hodgkin lymphoma is a type of cancer that starts in white blood cells called lymphocytes, which are a part of the body's immune system.
The interim data from the trial is from 60 response-evaluable patients. The complete response rate was recorded at 62% and 22% of patients had a partial response.
In addition, 8% subjects showed a progressive disease, while 8% showed stable disease symptoms. The estimated six-month progression-free survival rate was 89%.
No patients discontinued the treatment due to infusion-related reactions or immune-related adverse events.
Bristol-Myers Squibb and Seattle Genetics are enrolling patients in the ongoing clinical trial with relapsed or refractory disease, including diffuse large B-cell lymphoma, and other rare subtypes of B-cell lymphoma, including mediastinal B-cell lymphoma and mediastinal gray zone lymphoma.
The companies have also initiated a pivotal phase 3 trial evaluating Adcetris as a monotherapy versus Adcetris in combination with Opdivo in relapsed or refractory Hodgkin lymphoma.